D.G. Daniel

937 total citations
25 papers, 709 citations indexed

About

D.G. Daniel is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pharmacology. According to data from OpenAlex, D.G. Daniel has authored 25 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Psychiatry and Mental health, 7 papers in Cognitive Neuroscience and 5 papers in Pharmacology. Recurrent topics in D.G. Daniel's work include Schizophrenia research and treatment (15 papers), Functional Brain Connectivity Studies (5 papers) and Treatment of Major Depression (4 papers). D.G. Daniel is often cited by papers focused on Schizophrenia research and treatment (15 papers), Functional Brain Connectivity Studies (5 papers) and Treatment of Major Depression (4 papers). D.G. Daniel collaborates with scholars based in United States, Germany and United Kingdom. D.G. Daniel's co-authors include Richard L. Suddath, Manuel F. Casanova, John R. Kelsoe, D.R. Weinberger, T E Goldberg, Daniel R. Weinberger, Karen F. Berman, Richard Coppola, Craig N. Karson and D.R. Weinberger and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Schizophrenia Bulletin.

In The Last Decade

D.G. Daniel

25 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D.G. Daniel United States	10	386	348	160	135	70	25	709
EM Meisenzahl Germany	10	275 0.7×	292 0.8×	130 0.8×	112 0.8×	73 1.0×	17	644
R. Erkwoh Germany	10	309 0.8×	247 0.7×	112 0.7×	62 0.5×	43 0.6×	26	558
Parita Shah Canada	16	338 0.9×	247 0.7×	123 0.8×	102 0.8×	63 0.9×	38	762
C. Wurthmann Germany	11	311 0.8×	196 0.6×	56 0.3×	172 1.3×	85 1.2×	27	733
Arantzazu Zabala Spain	19	549 1.4×	232 0.7×	120 0.8×	55 0.4×	83 1.2×	26	781
Thérèse A. van Amelsvoort Netherlands	14	246 0.6×	224 0.6×	88 0.6×	126 0.9×	102 1.5×	18	628
A. Moffoot United Kingdom	14	293 0.8×	441 1.3×	113 0.7×	107 0.8×	70 1.0×	18	827
H. M. Olbrich Germany	13	131 0.3×	307 0.9×	102 0.6×	199 1.5×	79 1.1×	32	601
Mitsutoshi Okazaki Japan	16	413 1.1×	217 0.6×	107 0.7×	151 1.1×	36 0.5×	44	644
Nikolaj Bak Denmark	15	499 1.3×	384 1.1×	100 0.6×	130 1.0×	71 1.0×	30	865

Countries citing papers authored by D.G. Daniel

Since Specialization

Citations

This map shows the geographic impact of D.G. Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.G. Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.G. Daniel more than expected).

Fields of papers citing papers by D.G. Daniel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.G. Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.G. Daniel. The network helps show where D.G. Daniel may publish in the future.

Co-authorship network of co-authors of D.G. Daniel

This figure shows the co-authorship network connecting the top 25 collaborators of D.G. Daniel. A scholar is included among the top collaborators of D.G. Daniel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.G. Daniel. D.G. Daniel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Daniel, D.G., Olivera Marković, David Crandall, et al.. (2007). Transitioning from intramuscular (IM) to oral aripiprazole in patients with schizophrenia. European Psychiatry. 22. S124–S125. 1 indexed citations

Nemeroff, Charles B., John W. Newcomer, Jeffrey A. Lieberman, et al.. (2005). From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. CNS Spectrums. 10(S17). 1–20. 78 indexed citations

Daniel, D.G., S. Brook, Lewis Warrington, Antony Loebel, & Stephen A. Murray. (2004). Intramuscular ziprasidone in agitated patients with bipolar diagnoses. Annals of Emergency Medicine. 44(4). S22–S22. 1 indexed citations

Weiden, Peter J., et al.. (2002). Health status indices in stable outpatients switched to ziprasidone. European Psychiatry. 17. 100–100. 1 indexed citations

Rychlik, Reinhard, et al.. (2001). [Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management].. DMW - Deutsche Medizinische Wochenschrift. 126(33). 899–904. 2 indexed citations

Lorenz, J., et al.. (2001). Treatment Outcomes in Acute Exacerbations of Chronic Bronchitis: Comparison of Macrolides and Moxifloxacin from the Patient Perspective. Journal of International Medical Research. 29(2). 74–86. 29 indexed citations

Lucey, James V., S. Brook, D.G. Daniel, Karen R. Reeves, & Edmund P. Harrigan. (2000). Intramuscular (IM) ziprasidone: A novel treatment for the short-term management of agitated psychotic patients. Schizophrenia Research. 41(1). 208–208. 5 indexed citations

Daniel, D.G., S. Brook, & Karen R. Reeves. (2000). An overview of the efficacy and safety of rapid-acting intramuscular ziprasidone. European Neuropsychopharmacology. 10. 289–289. 4 indexed citations

Daniel, D.G., R C Stern, & Theresa R. Kramer. (1999). Switching from olanzapine to ziprasidone: An interim analysis of a 6-week study. European Neuropsychopharmacology. 9. 265–265. 7 indexed citations

10.

Daniel, D.G., J.A. Lieberman, & R. Birnbaum. (1999). Improvement in markers of health status 6 weeks after switching from olanzapine to ziprasidone. European Neuropsychopharmacology. 9. 265–265. 2 indexed citations

11.

Daniel, D.G., et al.. (1996). Probable neuroleptic induced tardive dyskinesia in association with combined SSRI and risperidone treatment. Schizophrenia Research. 18(2-3). 149–149. 1 indexed citations

12.

Daniel, D.G., et al.. (1995). Self-reported cognitive impairment predicts patient preference between risperidone and clozapine. Schizophrenia Research. 15(1-2). 147–148. 2 indexed citations

13.

Daniel, D.G.. (1994). Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders. Biological Psychiatry. 35(9). 667–667. 14 indexed citations

14.

Weinberger, D.R., KF Berman, & D.G. Daniel. (1992). MESOPREFRONTAL CORTICAL DOPAMINERGIC ACTIVITY AND PREFRONTAL HYPOFUNCTION IN SCHIZOPHRENIA. Clinical Neuropharmacology. 15. 568A–569A. 32 indexed citations

15.

Casanova, Manuel F., D.G. Daniel, Terry E. Goldberg, Richard L. Suddath, & Daniel R. Weinberger. (1989). Shape analysis of the middle cranial fossa of schizophrenic patients. Schizophrenia Research. 2(4-5). 333–338. 16 indexed citations

16.

Suddath, Richard L., Manuel F. Casanova, T E Goldberg, et al.. (1989). Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. American Journal of Psychiatry. 146(4). 464–472. 351 indexed citations

17.

Daniel, D.G., Karen F. Berman, & Daniel R. Weinberger. (1989). The effect of apomorphine on regional cerebral blood flow in schizophrenia. Journal of Neuropsychiatry. 1(4). 377–384. 58 indexed citations

18.

Karson, Craig N., Richard Coppola, D.G. Daniel, & Daniel R. Weinberger. (1988). Computerized EEG in Schizophrenia. Schizophrenia Bulletin. 14(2). 193–197. 57 indexed citations

19.

Daniel, D.G., et al.. (1987). Capgras Delusion and Seizures in Association With Therapeutic Dosages of Disulfiram. Southern Medical Journal. 80(12). 1577–1579. 19 indexed citations

20.

Benor, D, et al.. (1972). The variable effects of LSD-25 on the behavior of a heterogeneous group of childhood schizophrenics.. PubMed. 4(1-2). 10–6 passim. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact